Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 19;34(5):697–707. doi: 10.1002/mds.27695

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

LID reversibility study. (A) Treatment timeline. (B) Peak‐dose LID severity (80 minutes postlevodopa) across time. (C) Daily time course of LID behavior ranging from 20 to 200 minutes postlevodopa on each rating day. (D) Individual attributes of LID. As seen in this depiction of peak LID behaviors on day 53 postvector, the impact of CaV1.3 channel silencing appears to uniformly reduce all aspects of LID and is not selective on any particular attribute. As shown in the timeline, (A) all rats received daily high‐dose (12 mg/kg) levodopa at all times indicated. Data represent the mean ± SEM. Statistics: Kruskal‐Wallis tests with Dunn's multiple‐comparison post hoc as shown in graphs. LD, levodopa; Scr, rAAV‐Scrambled‐shRNA (n = 12); CaV, rAAV‐CaV1.3‐shRNA (n = 11). [Color figure can be viewed at wileyonlinelibrary.com]